DENVER--(BUSINESS WIRE)--March 6, 2006--Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, today reported 2005 full-year results. As of December 31, 2005, the Company had cash, cash equivalents and investments of $182.3 million. Net loss for the year ended December 31, 2005, was $63.0 million, or $1.68 per share, compared to a net loss of $57.7 million, or $2.00 per share last year.
